Executive Editor
Tao Pang Ph.D.
Associate Professor, China Pharmaceutical University. Visiting Fellow, National Institute of Mental Health · USA
Editorial leadership for Journal of Advanced Pharmaceutical Science And Technology ISSN 2328-0182
Research interests
- Drug Screening
- Drug Development To Seek Novel Small Molecules Or Natural Products For The Treatment Of Neurodegener
Biography
- Dr. Pang’s research focuses on the discovery of novel compounds by high-throughput screening or high-content screening in terms of molecular target-based assay or phenotypic assay, and drug development in order to provide therapeutics for the cerebral ischemic stroke and diabetes.
- He is also interested in the molecular mechanisms involved in brain inflammation, in order to prevent neuroinflammation and neuronal death, and promote brain functional recovery during cerebral ischemia.
Selected publications
- Microglia: Housekeeper of the Central Nervous System 2017 cited 208×
- Medioresinol as a novel PGC-1α activator prevents pyroptosis of endothelial cells in ischemic stroke through PPARα-GOT1 axis 2021 cited 99×
- Microglial CMPK2 promotes neuroinflammation and brain injury after ischemic stroke 2024 cited 79×
- MALAT1 Up-Regulator Polydatin Protects Brain Microvascular Integrity and Ameliorates Stroke Through C/EBPβ/MALAT1/CREB/PGC-1α/PPARγ Pathway 2019 cited 68×
- The PGC-1α Activator ZLN005 Ameliorates Ischemia-Induced Neuronal Injury In Vitro and In Vivo 2017 cited 47×
- Identification of a Small Molecule with Strong Anti-Inflammatory Activity in Experimental Autoimmune Encephalomyelitis and Sepsis through Blocking Gasdermin D Activation 2022 cited 27×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JAPST for your work?
This journal is guided by Tao Pang Ph.D. (Associate Professor, China Pharmaceutical University. Visiting Fellow, National Institute of Mental Health) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.